康缘药业
(600557)
| 流通市值：72.81亿 | | | 总市值：73.23亿 |
| 流通股本：5.66亿 | | | 总股本：5.69亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 877,554,089.34 | 3,897,668,541.61 | 3,109,535,857.51 | 2,259,796,227.6 |
| 营业收入 | 877,554,089.34 | 3,897,668,541.61 | 3,109,535,857.51 | 2,259,796,227.6 |
| 二、营业总成本 | 776,267,643.69 | 3,601,511,513.81 | 2,769,653,537.12 | 1,996,276,733.86 |
| 营业成本 | 226,572,240.8 | 1,043,897,392 | 802,158,552.41 | 575,231,266.78 |
| 税金及附加 | 16,072,007.56 | 60,571,592.66 | 49,261,258.24 | 35,294,055.43 |
| 销售费用 | 329,015,960.82 | 1,535,179,459.1 | 1,177,466,926.09 | 854,434,478.61 |
| 管理费用 | 75,848,099.77 | 318,162,596.88 | 292,466,648.29 | 210,086,533.86 |
| 研发费用 | 131,914,970.39 | 638,103,967.37 | 466,741,332.21 | 339,195,413.76 |
| 财务费用 | -3,155,635.65 | 5,596,505.8 | -18,441,180.12 | -17,965,014.58 |
| 其中:利息费用 | 3,049,590.93 | 22,297,041.41 | - | - |
| 其中:利息收入 | 6,236,054.49 | 17,389,064.63 | 18,807,106.48 | 18,269,273.17 |
| 加:投资收益 | 750,780.99 | 20,520,880.49 | 10,263,953.22 | 6,114,952.49 |
| 资产处置收益 | -6,931.75 | 1,083,999.48 | 703,685.04 | 703,685.05 |
| 资产减值损失(新) | - | -20,741,965.38 | - | - |
| 信用减值损失(新) | -1,169,564.77 | 3,240,115.75 | 490,394.26 | -467,888.64 |
| 其他收益 | 3,462,526.83 | 84,257,281.89 | 70,960,741.08 | 42,640,880.99 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 104,323,256.95 | 384,517,340.03 | 422,301,093.99 | 312,511,123.63 |
| 加:营业外收入 | 188,243.64 | 11,983,081.49 | 11,776,485.18 | 10,809,360.42 |
| 减:营业外支出 | 725,758.05 | 11,736,443.82 | 6,818,856.27 | 6,508,013.46 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 103,785,742.54 | 384,763,977.7 | 427,258,722.9 | 316,812,470.59 |
| 减:所得税费用 | 18,233,357.36 | 3,840,968.58 | 63,275,423.14 | 45,517,387.72 |
| 六、净利润 | 85,552,385.18 | 380,923,009.12 | 363,983,299.76 | 271,295,082.87 |
| 持续经营净利润 | 85,552,385.18 | 380,923,009.12 | 363,983,299.76 | 271,295,082.87 |
| 归属于母公司股东的净利润 | 83,412,980.21 | 391,862,071.18 | 357,144,879.13 | 265,423,194.43 |
| 少数股东损益 | 2,139,404.97 | -10,939,062.06 | 6,838,420.63 | 5,871,888.44 |
| (一)基本每股收益 | 0.15 | 0.68 | 0.62 | 0.46 |
| (二)稀释每股收益 | 0.15 | 0.68 | 0.62 | 0.46 |
| 九、综合收益总额 | 85,552,385.18 | 380,923,009.12 | 363,983,299.76 | 271,295,082.87 |
| 归属于母公司股东的综合收益总额 | 83,412,980.21 | 391,862,071.18 | 357,144,879.13 | 265,423,194.43 |
| 归属于少数股东的综合收益总额 | 2,139,404.97 | -10,939,062.06 | 6,838,420.63 | 5,871,888.44 |
| 公告日期 | 2025-04-30 | 2025-04-03 | 2024-10-31 | 2024-07-27 |
| 审计意见(境内) | | 标准无保留意见 | | |